Lixte Biotech

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. It uses biomarker technology to identify enzyme targets and designs novel compounds to attack those targets. The firm focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases, and the LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in Pasadena, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.

Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. (“Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer.

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial  by Major Pharma Company-

LIXTE Biotechnology Provides Update On Recent Activities and Developments

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26 th Annual Global Investment Conference-

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities, including notable pre-clinical developments.

LIXTE Biotechnology Holdings Provides Update on Recent Activities

Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard's Dana Farber Cancer Institute in Boston

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

-- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's progress with its proprietary compound, LB-100.

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Conference In Dublin, Ireland on February 27 - 29, 2024 Focuses on How to Bring Basic Science Discoveries to the Clinic

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Agreement Focuses on Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, CA, Feb. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH). Under the terms of the license agreement, LIXTE has licensed exclusively NIH's intellectual property rights claimed for a Cooperative Research and Development Agreement (CRADA) subject invention co-developed with Lixte, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs.

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to assess whether adding LIXTE's LB-100 to GSK's programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

PASADENA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage biotechnology company developing a novel class of cancer therapy called PP2A inhibitors, today announced the passing of its founder and Executive Chairman, John S. Kovach, M.D.

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Biotechnology V eteran Bas van der Baan B rings P recision O ncology E xpertise ; Founder John S . Kovach Named Executive Chairman

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

PASADENA, CA, July 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced the closing of its previously announced registered direct offering of 583,334 shares of common stock (or common stock equivalents in lieu thereof) and concurrent private placement of common warrants to purchase up to 583,334 shares of common stock (together with the registered direct offering, the “Offering”) at a purchase price of $6.00 per common share, priced “at-the-market” under Nasdaq rules. The common warrants issued pursuant to the concurrent private placement have an exercise price of $6.00 per share, are exercisable immediately upon issuance and will expire 5 years from issuance.

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) and currently meets all other applicable criteria for continued listing.

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc.  ( Nasdaq: L IXT ) (“LIXTE”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol ( NCT05809830 ) to determine the appropriate dose of LB-100 given with a standard dose of doxorubicin. Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

PASADENA, CA, June 02, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT) announced today that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023.

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

Results A dd to G rowing Body of E vidence that I nhibiting PP2A with LB - 100 M ay B e a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

First clinical trial seeking to determine if the potentiation of cytotoxic chemotherapy by LB-100 occurs in cancer patients as has been shown in multiple animal studies across a spectrum of cancers

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

News for Lixte Biotech Stock (LIXT)